Plasma concentrations and pharmacokinetics of dimethylsulfoxide and its metabolites in patients undergoing peripheral-blood stem-cell transplants

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 610-615

  Egorin, Merrill J ^a   Rosen, D Marc ^a   Sridhara, Rajeshwari ^a   Sensenbrenner, Lyle ^a   Cottler Fox, Michele ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DIMETHYL SULFOXIDE; ETOPOSIDE; MELPHALAN; THIOTEPA;

ARTICLE; AUTOTRANSPLANTATION; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CRYOPRESERVATION; DRUG BLOOD LEVEL; GRAFT PRESERVATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; TESTIS CARCINOMA; WHOLE BODY RADIATION;

EID: 0031918425     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.610     Document Type: Article

References (61)

1. MacGregor WS: The chemical and physical properties of DMSO. Ann NY Acad Sci 141:3-12, 1967
2. Leake CD (ed): Biological actions of dimethyl sulfoxide. Ann NY Acad Sci 141:1-671, 1967
3. Jacob SW, Herschler R (eds): Biological actions of dimethyl sulfoxide. Ann NY Acad Sci 243:5-508, 1975
4. de la Torre JC (ed): Biological actions and medical applications of dimethyl sulfoxide. Ann NY Acad Sci 411:1-404, 1983
5. Stewart BH, Branson AC, Hewitt CB, et al: The treatment of patients with interstitial cystitis, with special reference to intravesical DMSO. J Urol 107:377-380, 1972
6. Stewart BH, Shirley SW: Further experience with intravesical dimethyl sulfoxide in the treatment of interstitial cystitis. J Urol 116:36-38, 1976
7. Lovelock JE, Bishop MWH: Prevention of freezing damage to cells by dimethyl sulphoxide. Nature 183:1394-1395, 1959
8. Ashwood-Smith MJ: Radioprotective and cryoprotective properties of dimethyl sulfoxide in cellular systems. Ann NY Acad Sci 141:42-62, 1967
9. Malinin TI, Perry VP: Toxicity of dimethyl sulfoxide on HeLa cells. Cryobiology 4:90-96, 1967
10. Vos O, Kaalen MCAC: Prevention of freezing damage to proliferating cells in tissue culture. A quantitative study of a number of agents. Cryobiology 1:249-260, 1965
11. Brown BL, Nagle SC: Preservation of mammalian cells in a chemically defined medium with dimethylsulfoxide. Science 149:1266-1267, 1965
12. Bouroncle BA: Preservation of living cells at -79°C with dimethyl sulfoxide. Proc Soc Exp Biol Med 119:958-961, 1965
13. Hucker HB, Miller JK, Hochberg A, et al: Studies on the absorption, excretion and metabolism of dimethylsulfoxide (DMSO) in man. J Pharmacol Exp Ther 155:309-317, 1967
14. Hucker HB, Ahmad PM, Miller EA, et al: Metabolism of dimethyl sulfoxide to dimethyl sulfone in the rat and man. Nature 209:619-620, 1966
15. Wood DC: Fate and metabolism of DMSO, in Jacob SW, Rosenbaum EE, Wood DC (eds): Dimethyl Sulfoxide, vol 1, Basic Concepts of DMSO. New York, NY, Marcel Dekker, 1971, pp 133-145
16. Wong KK, Wang GM, Dreyfuss J, et al: Absorption, excretion, and biotransformation of dimethyl sulfoxide in man and miniature pigs after topical application as an 80% gel. J Invest Dermatol 56:44-48, 1971
17. Gerhards E, Gibian H: The metabolism of dimethyl sulfoxide and its metabolic effects in man and animals. Ann NY Acad Sci 141:65-76, 1967
18. Kolb KH, Jaenicke G, Kramer M, et al: Absorption, distribution and elimination of labeled dimethyl sulfoxide in man and animals. Ann NY Acad Sci 141:85-95, 1967
19. 14-labeled dimethyl sulfoxide in tissues of intact animals. Cryobiology 5:328-335, 1968
20. McDermott HL, Finkbeiner AJ, Zanette B: The fate of dimethyl sulfoxide applied to the skin of the rat. Can J Physiol Pharmacol 45:475-478, 1967
21. Hucker HB, Ahmad PM, Miller EA: Absorption, distribution and metabolism of dimethylsulfoxide in the rat, rabbit and guinea pig. J Pharmacol Exp Ther 154:176-184, 1966
22. 35S in the rat. Ann NY Acad Sci 141:77-84, 1967
23. Williams KIH, Burstein SH, Layne DS: Metabolism of dimethyl sulfide, dimethyl sulfoxide, and dimethyl sulfone in the rabbit. Arch Biochem Biophys 117:84-87, 1966
24. Layman DL, Jacob SW: The absorption, metabolism and excretion of dimethyl sulfoxide by rhesus monkeys. Life Sci 37:2431-2437, 1985
25. Blythe LL, Craig AM, Christensen JM, et al: Pharmacokinetic disposition of dimethyl sulfoxide administered intravenously to horses. Am J Vet Res 47:1739-1743, 1986
26. Williams KIH, Whittemore KS, Mellin TN, et al: Oxidation of dimethyl sulfoxide to dimethyl sulfone in the rabbit. Science 149:203-204, 1965
27. Distefano V, Borgstedt HH: Reduction of dimethylsulfoxide to dimethylsulfide in the cat. Science 144:1137-1138, 1964
28. Tiews J, Scharrer E, Harre N, et al: Metabolism and excretion of dimethyl sulfoxide in cows and calves after topical and parenteral application. Ann NY Acad Sci 243:139-150, 1975
29. Shah VP, Midha KK, Dighe S, et al: Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies J Pharm Sci 81:309-312, 1992
30. D'Argenio DZ, Schumitzky A: A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Meth Prog Biomed 9:115-134, 1979
31. D'Argenio DZ, Schumitzky A: ADAPT II User's Guide. Los Angeles, CA, Biomedical Simulations Resource, University of Southern California, 1990
32. Akaike H: A new look at the statistical model identification. IEEE Transact Automatic Control 19:716-723, 1974
33. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Marcel Dekker, 1982, pp 271-318
34. Scheiner LB: The population approach to pharmacokinetic data analysis: Rationale and standard data analysis methods. Drug Metab Rev 15:153-171, 1984
35. Grasela TH Jr, Antal EJ, Townsend RJ, et al: An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies. Clin Pharmacol Ther 39:605-612, 1986
36. Tanaka M, Levy J, Terada M, et al: Induction of erythroid differentiation in murine virus infected erythroleukemia cells by highly polar compounds. Proc Natl Acad Sci USA 72:1003-1006, 1975
37. Collins SJ, Ruscetti FW, Gallagher RE, et al: Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci USA 75:2485-2492, 1979
38. Borenfreund E, Steinglass M, Korngold G, et al: Effect of dimethyl sulfoxide and dimethylformamide on the growth and morphology of tumor cells. Ann NY Acad Sci 243:164-171, 1975
39. Friend C, Scher W: Stimulation by dimethyl sulfoxide of erythroid differentiation and hemoglobin synthesis in murine virus-induced leukemic cells. Ann NY Acad Sci 243:155-163, 1975
40. C) preservation after slow freezing of bone marrow in the gas phase of liquid nitrogen. Exp Hematol 10:360-366, 1982
41. Weaver CH, Buckner CD, Longin K, et al: Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 82:1981-1984, 1993
42. Ettinger DS, Orr DW, Rice AP, et al: Phase I study of N-methylformamide in patients with advanced cancer. Cancer Treat Rep 69:489-493, 1985
43. McVie JG, Ten Bokkel Huinink WW, Simonetti G, et al: Phase I trial of N-methylformamide. Cancer Treat Rep 68:607-610, 1984
44. O'Dwyer PJ, Donehower M, Sigman LM, et al: Phase I trial of N-methylformamide. J Clin Oncol 3:853-857, 1985
45. Conley BA, Forrest A, Egorin MJ, et al: Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). Cancer Res 49:3436, 1989
46. Rowinsky EK, Ettinger DS, Grochow LS, et al: Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer. J Clin Oncol 4:1835-1844, 1986
47. Rowinsky EK, Ettinger DS, McGuire WP, et al: Prolonged infusion of hexamethylene bisacetamide: A phase I and pharmacological study. Cancer Res 47:5788-5795, 1987
48. Young CW, Fanucchi MP, Walsh TD, et al: Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administered by ten-day continuous intravenous infusion at twenty-eight intervals. Cancer Res 48:7304-7309, 1988
49. Novogrodsky A, Dvir A, Ravid A, et al: Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer 51:9-14, 1983
50. Miller AA, Kurschel E, Osieka R, et al: Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 23:1283-1287, 1987
51. Perrine SP, Ginder GD, Faller DV, et al: A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 328:81-86, 1993
52. Sher GD, Ginder GD, Little J, et al: Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N Engl J Med 332:1606-1610, 1995
53. Thibault A, Cooper MR, Figg WD, et al: A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54:1690-1694, 1994
54. Thibault A, Samid D, Cooper MR, et al: Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75:2932-2938, 1995
55. Carducci M, Bowling M, Eisenberger M, et al: Phenylbutyrate (PB) for refractory solid tumors: A phase I clinical and pharmacological evaluation. Proc Am Assoc Cancer Res 37:167-168, 1996 (abstr 1152)
56. Sanders D, Tansan S, Arthur V, et al: Phase I clinical trial of arginine butyrate in patients with refractory neoplasms. Proc Am Soc Clin Oncol 14:476, 1995 (abstr 1547)
57. Dover GJ, Brusilow S, Charache S: Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84:339-343, 1994
58. Collins AF, Pearson HA, Giardina P, et al: Oral sodium butyrate therapy in homozygous beta thalassemia: A clinical trial. Blood 85:43-49, 1995
59. Sanders DA, Arthur V, Tansan S, et al: Phase I clinical trial of the differentiation agent isobutyramide in patients with refractory neoplasms. Proc Am Assoc Cancer Res 36:215, 1995 (abstr 1280)
60. Yuan Z, Eiseman J, Plaisance K, et al: Plasma pharmacokinetics (PK) of butyrate after the administration of tributyrin and Na butyrate to mice and rats. Proc Am Assoc Cancer Res 35:429, 1994 (abstr 2556)
61. Newmark HL, Lupton JR, Young CW: Butyrate as a differentiating agent: Pharmacokinetics, analogues, and current status. Cancer Lett 78:1-5, 1994